Recent Developments in the Management of Severe Asthma

Overview

Journal Breathe (Sheff)

Specialty Pulmonary Medicine

Date 2022 Nov 7

PMID 36338257

Authors

Howraman Meteran

Louise Lindhardt Tonnesen

Pradeesh Sivapalan

Truls Sylvan Ingebrigtsen

Jens-Ulrik Staehr Jensen

Affiliations

Soon will be listed here.

Abstract

https://bit.ly/3KE1BH4.

Citing Articles

Sub-Optimal Disease Control and Low Blood Eosinophil Testing Frequency in Chinese Adult Patients with Asthma Receiving GINA Step 4/5 Treatment: A Real-World Study.

Benson V, Siddall J, Haq A, Small M, Tang Z, Ye T J Asthma Allergy. 2024; 17:1041-1054.

PMID: 39464421 PMC: 11512527. DOI: 10.2147/JAA.S474338.

Understanding the Clinical Implications of Individual Patient Characteristics and Treatment Choice on the Risk of Exacerbation in Asthma Patients with Moderate-Severe Symptoms.

Singh D, Oosterholt S, Pavord I, Garcia G, Pg A, Della Pasqua O Adv Ther. 2023; 40(10):4606-4625.

PMID: 37589831 PMC: 10499702. DOI: 10.1007/s12325-023-02590-2.

References

Fleming L, Murray C, Bansal A, Hashimoto S, Bisgaard H, Bush A . The burden of severe asthma in childhood and adolescence: results from the paediatric U-BIOPRED cohorts. Eur Respir J. 2015; 46(5):1322-33. DOI: 10.1183/13993003.00780-2015. View

Blazquez A, Mayer L, Berin M . Thymic stromal lymphopoietin is required for gastrointestinal allergy but not oral tolerance. Gastroenterology. 2010; 139(4):1301-9. DOI: 10.1053/j.gastro.2010.06.055. View

Brightling C, Gaga M, Inoue H, Li J, Maspero J, Wenzel S . Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials. Lancet Respir Med. 2020; 9(1):43-56. DOI: 10.1016/S2213-2600(20)30412-4. View

Meteran H, Sivapalan P, Jensen J . Treatment Response Biomarkers in Asthma and COPD. Diagnostics (Basel). 2021; 11(9). PMC: 8464838. DOI: 10.3390/diagnostics11091668. View

Serra-Batlles J, Plaza V, Morejon E, Comella A, Brugues J . Costs of asthma according to the degree of severity. Eur Respir J. 1999; 12(6):1322-6. DOI: 10.1183/09031936.98.12061322. View

Busse W . Biological treatments for severe asthma: A major advance in asthma care. Allergol Int. 2019; 68(2):158-166. DOI: 10.1016/j.alit.2019.01.004. View

Meteran H, Meteran H, Porsbjerg C, Backer V . Novel monoclonal treatments in severe asthma. J Asthma. 2017; 54(10):991-1011. DOI: 10.1080/02770903.2017.1296157. View

Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler M . Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. N Engl J Med. 2021; 384(19):1800-1809. DOI: 10.1056/NEJMoa2034975. View

Heffler E, Paoletti G, Giorgis V, Puggioni F, Racca F, Del Giacco S . Real-life studies of biologics used in asthma patients: key differences and similarities to trials. Expert Rev Clin Immunol. 2019; 15(9):951-958. DOI: 10.1080/1744666X.2019.1653758. View

10.

Saunders R, Kaul H, Berair R, Gonem S, Singapuri A, Sutcliffe A . DP antagonism reduces airway smooth muscle mass in asthma by decreasing eosinophilia and myofibroblast recruitment. Sci Transl Med. 2019; 11(479). DOI: 10.1126/scitranslmed.aao6451. View

11.

Bateman E, Guerreros A, Brockhaus F, Holzhauer B, Pethe A, Kay R . Fevipiprant, an oral prostaglandin DP receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids. Eur Respir J. 2017; 50(2). DOI: 10.1183/13993003.00670-2017. View

12.

Tanaka J, Watanabe N, Kido M, Saga K, Akamatsu T, Nishio A . Human TSLP and TLR3 ligands promote differentiation of Th17 cells with a central memory phenotype under Th2-polarizing conditions. Clin Exp Allergy. 2008; 39(1):89-100. PMC: 7164823. DOI: 10.1111/j.1365-2222.2008.03151.x. View

13.

Albers F, Papi A, Taille C, Bratton D, Bradford E, Yancey S . Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA. Respir Res. 2019; 20(1):169. PMC: 6664536. DOI: 10.1186/s12931-019-1134-7. View

14.

Pignatti P, Visca D, Cherubino F, Zampogna E, Lucini E, Saderi L . Do blood eosinophils strictly reflect airway inflammation in COPD? Comparison with asthmatic patients. Respir Res. 2019; 20(1):145. PMC: 6617671. DOI: 10.1186/s12931-019-1111-1. View

15.

Erpenbeck V, Popov T, Miller D, Weinstein S, Spector S, Magnusson B . The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthma. Pulm Pharmacol Ther. 2016; 39:54-63. DOI: 10.1016/j.pupt.2016.06.005. View

16.

Hinks T, Levine S, Brusselle G . Treatment options in type-2 low asthma. Eur Respir J. 2020; 57(1). PMC: 7116624. DOI: 10.1183/13993003.00528-2020. View

17.

Heaney L, Busby J, Hanratty C, Djukanovic R, Woodcock A, Walker S . Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial. Lancet Respir Med. 2020; 9(1):57-68. PMC: 7783382. DOI: 10.1016/S2213-2600(20)30397-0. View

18.

Bernholm K, Homoe A, Meteran H, Jensen C, Porsbjerg C, Backer V . -based asthma management results in faster improvement of airway hyperresponsiveness. ERJ Open Res. 2018; 4(4). PMC: 6168761. DOI: 10.1183/23120541.00147-2017. View

19.

Sofianou A, Martynenko M, Wolf M, Wisnivesky J, Krauskopf K, Wilson E . Asthma beliefs are associated with medication adherence in older asthmatics. J Gen Intern Med. 2012; 28(1):67-73. PMC: 3539042. DOI: 10.1007/s11606-012-2160-z. View

20.

Gonem S, Berair R, Singapuri A, Hartley R, Laurencin M, Bacher G . Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med. 2016; 4(9):699-707. DOI: 10.1016/S2213-2600(16)30179-5. View